Last reviewed · How we verify
lactate and bicarbonate buffered dialysis solutions
Lactate and bicarbonate buffered dialysis solutions, developed by Heidelberg University, are currently marketed products used in dialysis treatments. The key composition patent is set to expire in 2028, providing a period of exclusivity that supports market stability. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | lactate and bicarbonate buffered dialysis solutions |
|---|---|
| Also known as | BicaVera, Balance |
| Sponsor | Heidelberg University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- High Cut-Off Continuous Veno-venous Hemodialysis (CVVHD) in Patients Treated for Acute Renal Failure After Systemic Inflammatory Response Syndrome (SIRS)/Septic Shock (NA)
- Administration of pH-Neutral Peritoneal Dialysis Solutions Containing Lactate or Bicarbonate in Children (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: